Atrial fibrillation (AF) and hypertension often coexist and are both responsible for considerable morbidity and mortality. Aggressive treatment of hypertension, especially with a RAS-blocker, may postpone or prevent AF development and reduce thromboembolic complications. Focus on primary prevention of atrial fibrillation with optimal antihypertensive treatment may reduce morbidity, mortality and health care expenditures.